



IFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/618884-Conf. #5880
	Filing Date	July 14, 2003
	First Named Inventor	Victor E. Shashoua
	Art Unit	1614
	Examiner Name	D. A. Jagoe
Total Number of Pages in This Submission	Attorney Docket Number	N0260.70058US00

ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input checked="" type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below): Return Receipt Postcard Check in the amount of \$180.00
<div>Remarks</div>		


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	WOLF, GREENFIELD & SACKS, P.C.		
Signature			
Printed name	Roque El-Hayek		
Date	March 22, 2006	Reg. No.	55,151

Certificate of Mailing Under 37 CFR 1.8(a)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: 3/22/06 Signature: (Angela M. Griffith)



PTO/SB/17 (12-04v2)

Approved for use through 7/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004. Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). FEE TRANSMITTAL For FY 2005		Complete if Known	
		Application Number	10/618884-Conf. #5880
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		Filing Date	July 14, 2003
		First Named Inventor	Victor E. Shashoua
TOTAL AMOUNT OF PAYMENT (\$)		Examiner Name	D. A. Jagoe
		Art Unit	1614
		Attorney Docket No.	N0260.70058US00

METHOD OF PAYMENT (check all that apply)	
<input checked="" type="checkbox"/> Check	<input type="checkbox"/> Credit Card <input type="checkbox"/> Money Order <input type="checkbox"/> None <input type="checkbox"/> Other (please identify): _____
<input type="checkbox"/> Deposit Account	Deposit Account Number: <u>23/2825</u> Deposit Account Name: <u>Wolf, Greenfield & Sacks, P.C.</u>
For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)	
<input type="checkbox"/> Charge fee(s) indicated below	<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee
<input checked="" type="checkbox"/> Charge any additional fee(s) or underpayment of fee(s) under 37 CFR 1.16 and 1.17	<input checked="" type="checkbox"/> Credit any overpayments

FEE CALCULATION							
1. BASIC FILING, SEARCH, AND EXAMINATION FEES							
	FILING FEES		SEARCH FEES		EXAMINATION FEES		
		<u>Small Entity</u>		<u>Small Entity</u>		<u>Small Entity</u>	
Application Type	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fees Paid (\$)
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	
2. EXCESS CLAIM FEES							
						Fee (\$)	Small Entity Fee (\$)
Fee Description							
Each claim over 20 (including Reissues)						50	25
Each independent claim over 3 (including Reissues)						200	100
Multiple dependent claims						360	180
Total Claims		Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims		
_____ - 20 = _____		x _____	= _____		Fee (\$)	Fee Paid (\$)	
Indep. Claims		Extra Claims	Fee (\$)	Fee Paid (\$)			
_____ - 3 = _____		x _____	= _____				
3. APPLICATION SIZE FEE							
If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).							
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof		Fee (\$)	Fee Paid (\$)		
_____ - 100 = _____	/50	_____ (round up to a whole number) x _____		= _____			
4. OTHER FEE(S)							
Non-English Specification, \$130 fee (no small entity discount)							
Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement						180.00	

SUBMITTED BY			
Signature		Registration No. (Attorney/Agent)	55,151
Name (Print/Type)	Roque El-Hayek	Telephone	(617) 646-8308
		Date	March 22, 2006

Certificate of Mailing Under 37 CFR 1.8(a)	
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Dated: <u>3/22/06</u>	Signature: (Angela M. Griffith)




DOCKET NO.: N0260.70058US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Victor E. Shashoua et al.
Serial No.: 10/618,884
Confirmation No.: 5880
Filed: July 14, 2003
For: DHA-PHARMACEUTICAL AGENT CONJUGATES OF
TAXANES
Examiner: Donna A. Jagoe
Art Unit: 1614

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 27th day of March, 2006.


Angela Griffith

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed more than three months after the filing date of this application and after the mailing date of the first Office action, but before the mailing date of any final action under 37 C.F.R. §1.113, a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in this application.

The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following co-pending applications that may contain subject matter related to this application:

<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>	<u>Atty Docket No.</u>
10/107,537	March 25, 2002	Swindell, et al.	N0260.70051US00
10/108,255	March 25, 2002	Swindell, et al.	N0260.70052US00
10/455,250	June 5, 2003	Nigel L. Webb, et al.	N0260.70064US00

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

Serial No.: 10/618,884
Conf. No.: 5880

- 3 -

Art Unit: 1614

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

By:



Roque El-Hayek, Reg. No. 55,151
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: N0260.70058US00
Date: March 22, 2006
xNDDx



INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/618,884		ATTY. DOCKET NO.: N0260.70058US00	
				FILING DATE: July 14, 2003		CONFIRMATION NO.: 5880	
				APPLICANT: Victor E. Shashoua et al.			
				GROUP ART UNIT: 1614		EXAMINER: Donna A. Jagoe	
Sheet	1	of	7				

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

	*	3,539,573		Schmutz	11/10/1970
	*	3,621,048		Bauman	11/16/1971
	*	4,097,597		Horrom, et al.	06/27/1978
	*	4,218,234	A	Nadasy, et al.	08/19/1980
	*	4,346,085		Growdon, et al.	08/24/1982
	*	4,351,831		Growden, et al.	09/28/1982
	*	4,550,109		Folkers, et al.	10/29/1985
	*	4,554,272		Bock, et al.	11/19/1985
	*	4,558,049		Bernardi, et al.	12/10/1985
	*	4,684,646		Chang, et al.	08/04/1987
	*	4,868,161		E. Roberts	09/19/1989
	*	4,902,505		Pardridge, et al.	02/20/1990
	*	4,933,324		Shashoua	06/12/1990
	*	4,939,174		Shashoua	07/03/1990
	*	5,169,762		Grey, et al.	12/08/1992
	*	5,284,876		Shashoua	02/08/1994
	*	5,532,372		Saji, et al.	07/02/1996
	*	5,532,374		Lee, et al.	07/02/1996
	*	5,545,719		Shashoua	08/13/1996
	*	5,603,959	A1	Horrobin, et al.	02/18/1997
	*	5,604,198		Poduslo, et al.	02/18/1997
	*	5,646,180		Chaturvedi	07/18/1997
	*	5,824,701	A	Greenwald et al.	10/20/1998
	*	5,827,819		Yatvin, et al.	10/27/1998
	*	5,955,459		Bradley, et al.	09/21/1999
	*	6,005,004		Katz et al.	12/21/1999
	*	6,024,977		Yatvin et al.	02/15/2000
	*	6,107,499		Shashoua	08/22/2000
	*	6,245,811	B1	Horrobin et al.	06/12/2001
	*	6,407,075	B1	Scott et al.	06/18/2002
	*	6,407,137	B2	Shashoua	06/18/2002
	*	6,448,392	B1	Hostettler et al.	09/10/2002
	*	6,576,636	B2	Webb et al.	06/10/2003
	*	6,602,902	B2	Shashoua et al.	08/05/2003
	*	6,627,601	B2	Shashoua	09/30/2003

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/618,884		ATTY. DOCKET NO.: N0260.70058US00	
				FILING DATE: July 14, 2003		CONFIRMATION NO.: 5880	
				APPLICANT: Victor E. Shashoua et al.			
				GROUP ART UNIT: 1614		EXAMINER: Donna A. Jagoe	
Sheet	2	of	7				

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	*	AU	770519		Protarga, Inc.	04/05/2001	
	*	AU	746472		Protarga, Inc.	06/15/1999	
	*	DE	24 56 947	A1	Pfizer, Inc.	06/12/1975	With English Abstract
	*	DE	29 32 869	A1	Ciba-Geigy AG	02/28/1980	
	*	EP	0909183	B1	Protarga, Inc.	04/21/1999	
	*	EP	0 599 576	A1	Scotia Holding, PLC	06/01/1994	
	*	EP	0 311 100	A2	F. Hoffman	04/12/1989	
	*	EP	0 091 694	A1	Eisai Co., Ltd.	10/19/1983	
	*	EP	0909183	B1	Protarga, Inc.	08/11/2004	
	*	EP	0 035 375	A1	Takeda Yakuhin Kogyo Kabushiki Kaisha	09/09/1981	
	*	EP	0 761 644	A	Kao Corporation	03/12/1997	
	*	FR	2 592 883	A	Ire Celltarg SA	07/17/1987	
	*	JP	75-9469		New OJI Paper Co., Ltd	07/29/1976	Abstract
	*	JP	8245378	A	Sagami Chem Res Centerfuji Yakuhin:KK	09/24/1996	Abstract
	*	JP	7082146		Sagami Chem Res Center	03/28/1995	Abstract
	*	JP	6072868		Maruha Corp.	03/15/1994	Abstract
	*	JP	61204136		Teijin Ltd.	09/10/1986	Abstract
	*	JP	10168047	A	Kao Corp	06/23/1998	Abstract
	*	JP	2256624	A	Sagami Chem Res Centre	10/17/1990	Abstract
	*	JP	55053208	A	Mitsubishi Chem Ind. Ltd.	04/18/1980	Abstract
	*	SU	477159	A	Phytopathology Inst.	10/14/1976	Abstract
	*	WO	02/087586	A1	Control Delivery Systems, Inc.	11/07/2002	
	*	WO	01/62085	A1	Medinox, Inc.	08/30/2001	
	*	WO	00/01417		Cyclacel Limited	01/13/2000	
	*	WO	00/53231		Protarga, Inc.	09/14/2002	
	*	WO	00/67802		Protarga, Inc.	11/16/2002	
	*	WO	98/09621		Scotia Holdings, PLC	04/12/1998	
	*	WO	99/26620		Neuromedia, Inc.	06/03/1999	
	*	WO	99/44600		Scotia Holding, PLC	09/10/1999	
	*	WO	89/07938		Shashoua	09/08/1989	
	*	WO	98/17325		Oregon Health Sciences University	04/30/1998	
	*	WO	97/33173	A	The Regents of the University of California	09/12/1997	
	*	WO	96/34855		Scotia Holding PLC	11/7/1996	
	*	WO	96/22303		Commonwealth of Scientific and Industrial Research	07/25/1996	

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/618,884		ATTY. DOCKET NO.: N0260.70058US00	
				FILING DATE: July 14, 2003		CONFIRMATION NO.: 5880	
				APPLICANT: Victor E. Shashoua et al.			
				GROUP ART UNIT: 1614		EXAMINER: Donna A. Jagoe	
Sheet	3	of	7				

FOREIGN PATENT DOCUMENTS

	*	WO	96/04001		Molecular/Structural Biotechnologies, Inc.	02/15/1996	
	*	WO	85/00520		The McLean Hospital Corp.	04/06/1989	
	*	WO	02/087586	A1	Control Delivery Systems, Inc.	11/07/2002	
	*	WO	92/06089	A	H. Lundbeck	04/16/1992	
	*	WO	98/32718	A	Norsk Hydro	07/30/1998	
	*	WO	98/43994	A	Genzyme Corporation	10/08/1998	
	*	WO	93/1168		Schering Aktiengesellschaft Berling Underbergkamen	06/24/1993	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.					Translation (Y/N)	
	*	AIHARA, M. et al., "Effects of liposteroid on skin lesions in autoimmune MRLlpr/lpr mice," <i>Journal of Dermatological Science</i> , 16, 1997, pp. 45-51.						
	*	FUNAUCHI, M. et al., "Effects of liposteroid on the hemophagocytic syndrome in systemic lupus erythematosus," <i>Lupus</i> , 12, 2003, pp. 483-485.						
	*	HAZARD Database, "Chemical Tertogens, Carcinogens, Mutagens: Dexamethasone palmitate," http://www.evol.nw.ru/labs/lab38/spirov/hazard/dexamethasone_palmitate.html , printed from website on August 31, 2004.						
	*	HOSHI, K. et al., "Double-Blind Study with Liposteroid in Rheumatoid Arthritis," <i>Drugs Exptl. Clin. Res.</i> , XI(9), 1985, pp. 621-626.						
	*	KARMALI, R.A., et al., "Effect of Omega-3 Fatty Acids on Growth of a Rat Mammary Tumor," <i>J Natl Cancer Inst</i> , 73(2), 1984, pp. 457-461. (Abstract)						
	*	MIZUSHIMA, Y. et al., "Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsion,"						
	*	UEDA et al., "Synthesis and Antitumor Evaluation of 2'-Oxycarbonylpaclitaxels (Paclitaxel-2'-Carbonates)," <i>Bioorganic & Medicinal Chemistry Letters</i> , Vol. 4, No. 15, 1994, pp. 1861-1864.						
	*	YAMATSU et al., "Polyprenyl Carboxylic Acid Amides," <i>Chemical Abstracts</i> , Vol. 100, No. 19 issued 7 May 1984, p. 555, Abstract No. 156839z, EP91, 694, dated 19 October 1983.						
	*	YOKOYAMA, K. et al., "Development of a Corticosteroid Incorporated in Lipid Microspheres (Liposteroid)," <i>Drugs Exptl. Clin. Res.</i> , XI(9), 1985, pp. 611-620.						
	*	"Cytosar-U cytarabine for injection, USP," Product insert, 2/2002.						
	*	"Dexamethasone palmitate: Chemical Teratogens, Carcinogens, Mutagens," CAS# [33755-46-3], ACX# [11012259], http://www.evol.nw.ru/labs/lab38/spirov/hazard/dexamethasone_palmitate.html						
	*	AIHARA, M., et al., "Effects of liposteroid on skin lesions in autoimmune MRLlpr/lpr mice," <i>J. of Dermatological Science</i> 16 (1997), pp. 45-51.						
	*	ALTHAUS, I.W. et al., "The amphiphilic properties of novenamides determine their activity as inhibitors of HIV-1 RNase H," <i>Experientia</i> , Vol. 52, 1996, pp. 329-335, XP008039697.						
	*	ATTARD, George S., et al., "Phase behaviour of novel phospholipid analogues." <i>Chemistry and Physics of Lipids</i> , vol. 76, 1995, pages 41-48.						
	*	BALDESSARINI, et al., "Dopamine and Pathophysiology of Dyskinesia..." <i>Ann. Rev. Neurosci.</i> 3:23-41 (1980).						
	*	BOLWELL, et al., "High dose cytarabine: a review," <i>Leukemia</i> 5 (5/1988), pp. 253-60 Abstract.						

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/618,884		ATTY. DOCKET NO.: N0260.70058US00	
				FILING DATE: July 14, 2003		CONFIRMATION NO.: 5880	
				APPLICANT: Victor E. Shashoua et al.			
				GROUP ART UNIT: 1614		EXAMINER: Donna A. Jagoe	
Sheet	4	of	7				

OTHER ART — NON PATENT LITERATURE DOCUMENTS

	*	BRIDGES, A.J. et al., "N ⁶ -(2,2-Diphenylethyl)adenosine, a Novel Adenosine Receptor Agonist with Antipsychotic-like Activity", <i>J. Med. Chem.</i> 30:1709-1711 (1987)		
	*	BRUTOVSKA, A. et al., "Isothiocyanates and Their Synthetic Producers. VIII. The Synthesis and the Study of Spectral Features of Substituted Monothiourethanes," <i>Chem. Zvesti</i> , vol. 23, 1969, pp. 736-741.		
	*	DATABASE BEILSTEIN, <i>Beilstein Institute for Organic Chemistry</i> , Frankfurt-Main, DE, 29 June 1989, XP002311506, Database accession no. 2146750 (BRN).		
	*	DATABASE BEILSTEIN, <i>Beilstein Institute for Organic Chemistry</i> , Frankfurt-Main, DE, 15 February 1990, XP002311507, Database accession no. 3166362 (BRN).		
	*	DATABASE BEILSTEIN, <i>Beilstein Institute for Organic Chemistry</i> , Frankfurt-Main, DE, 29 June 1989, XP002311508, Database accession no. 2270240 (BRN).		
	*	DATABASE BEILSTEIN: 29 June 1989 (1989-06-29), XP002329550; Database accession no. 2199386 (BRN), Abstract & SU 477 159 A (STREL'TSOV, BLIZNYUK) 1976		
	*	DATABASE HCAPLUS ACS, 6 September 1991, XP002311505, retrieved from STN, Database accession no. 115:91935/DN, RN 2411-58-7, 135346-35-9, 7418-03-3.		
	*	DATABASE HCAPLUS ACS: 11 October 2000 (2000-10-11); XP002329554; Retrieve from STN Database accession no. 134:193273/DN, Abstract, RN327082-01-9; & CHEN, ZAI-XIN ET AL: ZHONGGUO YIYAO GONGYE ZAZHI BIANJIBU, vol 31, no. 6, 2000, pages 265-268		
	*	DATABASE HCAPLUS ACS: 12 May 1984 (1984-05-12); XP002329551; Retrieved from STN Database accession no. 93:90207/DN; Abstract, RN52067-53-5, 74551-09-0 & JP 55 053208 A (Mitsubishi Chemical Ind. Co.); 18 April 1980 (1980-04-18)		
	*	DATABASE HCAPLUS ACS: 2 July 1998 (1998-07-02); XP002329553; Retrieved from STN Database accession no. 129:135899/DN, Abstract, RN210540-30-0, -31-1 & JP 10 168047 A (KAO Corp.), 23 June 1998 (1998-06-23)		
	*	DATABASE HCAPLUS ACS: 28 June 1991 (1991-06-28); XP002329552; Retrieved from STN Database accession no. 114:254032, Abstract, RN29271-27-0, 49802-20-2, 134036-50-3 & JP 02 256624 A (Sagami Chemical Research Center) 17 October 1990 (1990-10-17)		
	*	DeVITA, JR., et al., <i>Cancer Principles & Practice of Oncology</i> , 5 th Ed., pp. 443-444.		
	*	DHOPESHWARKER, G., "Fatty Acid Transport Through the Blood-Brain Barrier.", <i>Biochim Biophys. Acta</i> 255:572-579.		
	*	Domagala, John M., et al., "New Class of Anti-HIV-1 Agents Targeted Toward the Nucleocapsid Protein NCp7: The 2,2'-Dithiobisbenzamides." <i>Bioorganic & Medicinal Chemistry</i> , Vol. 5, No. 3, pages 569-579 (1997).		
	*	FUNAUCHI, M., et al., "Effects of liposteroid on the hemophagocytic syndrome in systemic lupus erythematosus," <i>Lupus</i> 12 (2003), pp. 483-485.		
	*	GARZON-ABURBEH, et al., "A Lymphotropic Product of L-Dopa: Synthesis" <i>J. Med. Chem.</i> 29: 687-691 (1986)		
	*	GUÉNARD, et al., "Effects of the Hydrophobicity of Taxoids on their Interaction with Tubulin", <i>Bioorganic & Medicinal Chemistry</i> Vol. 8, (2000) pp. 145-156.		
	*	GUFFY, M.M., et al., "Effect Of Cellular Fatty Acid Alteration On Adriamycin Sensitivity In Cultured L1210 Murine Leukemia Cells", <i>Cancer Res.</i> (1984), 44:1863-1866.		
	*	GUILLONNEAU, C. et al., "Synthesis of 9- O-Substituted Derivatives of 9-Hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxylic Acid (2-(Dimethylamino)ethyl)amide and Their 10- and 11-Methyl Analogues with Improved Antitumor Activity," <i>J. Med. Chem.</i> 1999, 42, pp. 2191-2203, XP-002311501.		
	*	GUNNE, et al., "Oral Dyskinesia in Rats Following Brain Lesions and Neuroleptic Drug Administration", <i>Psychopharmacology</i> 77:134-139 (1982)		
	*	HAAS, et al., "Effektivität intramuskulär verabreichten Cytosin-Arabinosids bei der ambulanten Behandlung von Kindern mit akuter Leukämie in Remission," <i>Onkology</i> (2/1980) pp. 53-57. (English summary included).		
	*	HESSE, et al., "Uptake in brain neurophysiological activity of two lipid esters of gamma-aminobutyric acid" <i>Neuropharmacol.</i> 27:6:637-40 (1988).		
	*	HO, et al., "Pharmacologic Studies of Cyclocytidine and Arabinosylcytosine in Dogs," <i>Drug Metabolism and Disposition</i> 3(4) (1975), pp. 309-313.		

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/618,884		ATTY. DOCKET NO.: N0260.70058US00	
				FILING DATE: July 14, 2003		CONFIRMATION NO.: 5880	
				APPLICANT: Victor E. Shashoua et al.			
				GROUP ART UNIT: 1614		EXAMINER: Donna A. Jagoe	
Sheet	5	of	7				

OTHER ART — NON PATENT LITERATURE DOCUMENTS

	*	HO, et al., "Pharmacology of 5'-Esters of 1-β-D-Arabinofuranosylcytosine," <i>Cancer Research</i> 37 (6/1977), pp. 1640-1643.		
	*	HONG, C.I. et al., "Synthesis and Biological Activity of N ⁶ -(n-Alkylureido)purine Ribonucleosides and Their 5γ-Phosphates," <i>J. Pharm. Sci.</i> , Vol. 67, No. 4, April 1978, pp. 569-571, XP008039688.		
	*	HOSHI, K., et al., "Double-blind study with liposteroid in rheumatoid arthritis," <i>Drugs Exptl. Clin. Res.</i> XI(9) (1985), pp. 621-626.		
	*	International Search Report in PCT/US02/09389, mailed February 10, 2004		
	*	JACOB, et al., "Alpha-Aminobutyric Acid Esters.3. Synthesis, brain uptake and pharmacological properties of C-18 Glyceryl lipid esters of BAGA with varying degree of unsaturation," <i>J. Med. Chem.</i> 30:1573-6 (1987).		
	*	JACOB, et al., "Synthesis, brain uptake and pharmacological properties of a glyceryl lipid containing GABA and the GABA-T inhibitor, gamma-vinyl-GABA," <i>J. Med. Chem.</i> 33:733-6 (1990).		
	*	Janusz, John J., et al., "Vanilloids. 1. Analogs of Capsaicin with Antinociceptive and Antiinflammatory Activity," <i>J. Med. Chem.</i> , Vol. 36, No. 18, pages 2595-2604 (1992).		
	*	Kageyama, Yuichi, et al., "Novel approaches to prodrugs of anticancer diaminodichloroplatinum(II) complexes activated by stereoselective enzymatic ester hydrolysis," <i>Journal of Inorganic Biochemistry</i> , Vol. 70, pp. 25-32 (1998).		
	*	Kalgutkar, Amit S., et al., "Ester and Amide Derivatives of the Nonsteroidal Antiinflammatory Drug, Indomethacin, as Selective Cyclooxygenase-2 Inhibitors," <i>Journal of Medicinal Chemistry</i> , pages 2860-2870 (2000)		
	*	Kariko, Katalin, et al, "n-DECYL-NHpppA2γ p5γ A2γ p5γ A A Phosphatase-Resistant, Active pppA2γp5γ A2γ p5γ A Analog," <i>Biochemical and Biophysical Research Communications</i> , Vol. 128, No. 2, pp. 695-698 (1985).		
	*	KATAOKA, et al., "Effect and Mode of Action of N ⁴ -Behenoyl-β-D-Arabinofuranosylcytosine," <i>Recent Results in Cancer Research</i> 70 (1980), pp. 147-151.		
	*	KONIGSTORFER et al., "Biosynthesis of Ependymins from Goldfish Brain", <i>J. Biol. Chem.</i> , vol. 264 (23): 13689-13692 (1989).		
	*	KONIGSTORFER et al., "Molecular Characterization Of An Ependymin Precursor from Goldfish Brain", <i>J. Neurochem.</i> , 52:310-312 (1989).		
	*	KRISTIAN et al., "Isothiocyanates and Their Synthetic Producers. X. Synthesis of 3-Substituted 2-Thioxo-4-Oxo-3,4-Dihydro-2H-1,3-Benzoxazines," <i>Collect. Czech. Chem. Commun.</i> , vol. 37, 1972, pp. 2972-2974.		
	*	LEE, HEEJOO et al., "Syntheses of 5-Fluorouracil-Fat Conjugates and Evaluation of Their <i>in vitro</i> Cytotoxic Activity," <i>Yakhak Hoechi</i> , vol. 34, 1990, pp. 395-400.	Abstract only	N
	*	LENNARTZ, <i>Chem. Ber.</i> , vol. 75, 1942, pp. 833-842.		N
	*	LEONARD, et al., "Identification and Characterization of mRNAs Regulated by Nerve Growth Factor in PC12 Cells", <i>Molecular and Cellular Biology</i> , 7(9):3156-67 (1987)		
	*	LIU, J. et al., "New Approaches for the Preparation of Hydrophobic Heparin Derivatives," <i>J. of Pharmaceutical Sciences</i> , Vol. 83, No. 7, July, 1994, pp. 1034-1039, XP008038024.		
	*	LOHR, et al., "Neuroleptic-Induced Movement Disorders...", <i>Psychiatry</i> , Vol. 3, 1-16 (1989).		
	*	MARDER, S.R., <i>J. Clin. Psychiatry</i> (supp 3), <i>Management of Schizophrenia</i> 57:9-13 (1996)		
	*	McGuigan, C. et al., "Phosphoramidates as potent prodrugs of anti-HIV nucleotides: studies in the amino region." <i>Antiviral Chemistry & Chemotherapy</i> , Vol. 7, No 1, pp. 31-36 (1996).		
	*	McGuigan, C., et al., "Synthesis and Evaluation of some masked phosphate esters of the anti-herpesvirus drug 882C (netivudine) as potential antiviral agents." <i>Antiviral Chemistry & Chemotherapy</i> , Vol. 9, pp. 233-243 (1998).		
	*	MEIER et al., "Molecular Cloning of Bovine and Chick Nerve Growth (NGF) . . .", <i>The EMBO Journal</i> , vol. 5, 7:1489-1493 (1986).		

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/618,884		ATTY. DOCKET NO.: N0260.70058US00	
				FILING DATE: July 14, 2003		CONFIRMATION NO.: 5880	
				APPLICANT: Victor E. Shashoua et al.			
				GROUP ART UNIT: 1614		EXAMINER: Donna A. Jagoe	
Sheet	6	of	7				

OTHER ART — NON PATENT LITERATURE DOCUMENTS

	*	MEYER, K. L. et al., "In Vitro Evaluation of Phosphocholine and Quaternary Ammonium Containing Lipids as Novel Anti-HIV Agents," <i>J. Med. Chem.</i> 1991, 34, pp. 1377-1383, XP-002311504.		
	*	Miroshnikova, Olga V., et al., "Structure-Activity Relationship in the Series of Eremomycin Carboxamides." <i>The Journal of Antibiotics</i> , Vol. 53, No. 3, pp. 286-293 (2000).		
	*	MIZUSHIMA, Y., et al., "Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsion," <i>Annals of the Rheumatic Diseases</i> , 41 (1982), pp. 263-267.		
	*	Nicolaou, Anna, et al., "Synthesis and Properties of Novel Lipopeptides and Lipid Mimetics." <i>Journal of Peptide Science</i> , Vol. 3, pp. 291-298 (1997).		
	*	PCT/GB97/02362 – Scotia Holdings, PLC - Search Report - February 20, 1998		
	*	PCT/GB99/00563 - Scotia Holdings, PLC - Search Report - August 19, 1999		
	*	PCT/US00/06160 - Protarga, Inc. - Search Report – October 4, 2001		
	*	PCT/US00/12752 - Protarga, Inc. - Search Report - October 31, 2000		
	*	PCT/US89/00757 – Shashoua - Search Report - June 14, 1989		
	*	PCT/US91/03346 – Shashoua - Search Report - September 6, 1991		
	*	PCT/US97/08792 - Neuromedica, Inc. - Search Report - October 28, 1997		
	*	PCT/US97/08866 - Neuromedica, Inc. - Search Report - September 3, 1997		
	*	PCT/US97/08867 - Neuromedica, Inc. - Search Report - January 9, 1998		
	*	PCT/US98/24412 - Neuromedica, Inc. - Search Report - February 22, 1999		
	*	PCT/US98/24421 - Neuromedica, Inc. - Search Report - March 3, 1999		
	*	PCT/US98/24490 - Neuromedica, Inc. - Search Report - February 26, 1999		
	*	PCT/US99/01786 - Neuromedica, Inc. - Search Report - July 6, 1999		
	*	PONPIPOM, M.M. et al., "Structure-Activity Relationships of C1 and C6 Side Chains of Zaragozic Acid A Derivatives," <i>J. Med. Chem.</i> 1994, 37, pp. 4031-4051, XP-002311499.		
	*	PUGLISI, G. et al., "Synthesis of Methotrexate γ,γ -Bis(Amides) and Correlation of Thermotropic and DPPC Biomembrane Interaction Parameters with Their Anticancer Activity," <i>Drug Development Research</i> 44, pp. 62-69 (1998), XP008039189.		
	*	Rasmusson, Gary H., "Azasteroids: Structure-Activity Relationships for Inhibition of 5 γ -Reductase and Androgen Receptor Binding," <i>J. Med. Chem.</i> , Vol. 29, pp. 2298-2315 (1986).		
	*	RENTSCH, et al., "Pharmacokinetics of N ⁴ -Octadecyl-1- β -D-Arabinofuranosylcytosine in Plasma and Whole Blood after Intravenous and Oral Administration to Mice," <i>J. Pharm. Pharmacol.</i> 49 (1997), pp. 1076-1081.		
	*	ROARK, W. H. et al., "Inhibitors of Acyl-CoA:Cholesterol Acyltransferase (ACAT). 2. Modification of Fatty Acid Anilide ACAT Inhibitors: Bioisosteric Replacement of the Amide Bond," <i>J. Med. Chem.</i> 1993, 36, pp. 1662-1668, XP002924002.		
	*	SASSE, A. et al., "Development of Chiral N-Alkylcarbamates as New Leads for Potent and Selective H ₃ -Receptor Antagonists: Synthesis, Capillary Electrophoresis, and in Vitro and Oral in Vivo Activity," <i>J. Med. Chem.</i> 1999, 42, pp. 593-600, XP-002311502.		
	*	SCOTT, et al., "Isolation and nucleotide sequence of cDNA encoding...", <i>Nature</i> 302, 538-540 (1983).		
	*	SEKI, J., et al., "A nanometer lipid emulsion, lipid nano-sphere (LNS®), as a parenteral drug carrier for passive drug targeting," <i>International Journal of Pharmaceutics</i> 273 (2004), pp. 75-83.		
	*	SERGERAERT, C. et al., "Synthesis and Anti-HIV Evaluation of D4T and D4T 5'-Monophosphate Prodrugs," <i>J. Med. Chem.</i> 1993, 36, pp. 826-830, XP-002311498.		
	*	SHASHOUA, et al., "Evidence for the In Vivo Polymerization of Ependymin: Brain Extracellular Glycoprotein," <i>Brain Research</i> , 522, 181-190 (1990)		
	*	SHASHOUA, V.E., "Ependymin, a Brain Extracellular Glycoprotein, and CNS Plasticity," reprinted from <i>Activity-Driven CNS Changes in Learning and Development</i> , vol. 627 of the <i>Annals of the New York Academy of Sciences</i> , Aug. 5, 1991).		

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/618,884		ATTY. DOCKET NO.: N0260.70058US00	
				FILING DATE: July 14, 2003		CONFIRMATION NO.: 5880	
				APPLICANT: Victor E. Shashoua et al.			
				GROUP ART UNIT: 1614		EXAMINER: Donna A. Jagoe	
Sheet	7	of	7				

OTHER ART — NON PATENT LITERATURE DOCUMENTS

	*	Shashoua, V.E., "The Role of Brain Extracellular Proteins...", <i>Cellular and Mol. Neurobiol.</i> , 5 (1/2):183-207 (1985).		
	*	SHASHOUA, V.E., "The role of ependymin in the development of long lasting synaptic charges" <i>J. Physiol. Paris</i> , 83:232-239 (1988-1989)		
	*	SIMONI, D. et al., "Geiparvarin Analogues. 2. Synthesis and Cytostatic Activity of 5-(4-Arylbutadienyl)-3(2H)-furanones and of N-Substituted 3-(4-Oxo-2-furyl)-2-buten-2-yl Carbamates," <i>J. Med. Chem.</i> 1991, 34, pp. 3172-3176, XP-002311503.		
	*	Smrt ^a , J., et al., "Synthesis of Some Nucleolipids." Collection Czechoslov. Chem. Commun., Vol. 45, pp. 927-931 (1980).		
	*	Supplementary partial European search report from related European Patent Application EP 02731170.3, dated June 22, 2005		
	*	Supplementary Partial European Search Report in Application No. PCT/US02/09389, mailed January 5, 2005.		
	*	TANAKA, T. et al., "Synthesis and Antioxidant Activity of Novel Amphipathic Derivatives of Tea Polyphenol," <i>Bioorganic & Medicinal Chemistry Letters</i> 8 (1998), pp. 1801-1806.		
	*	TERASAWA, et al., "Neurocalcin" a novel calcium binding protein from bovine brain" <i>J. Biol. Chem.</i> , 267:27 (1992), pages 19596-19599		
	*	TSUSHIMA, S. et al., "Syntheses and Biological Activities of N-Alkyl- and N-Alkenylcarbamoyl Phospholipids," <i>Chem. Pharm. Bull.</i> 32(7): pp. 2700-2713 (1984), XP-002311500.		
	*	Turesky, Samuel, et al., "In Vitro Chemical Inhibition of Plaque Formation." <i>J. Periodontol.</i> , Vol. 43, pp. 263-269 (1972).		
	*	WASHBURNE, S. S. et al., "Isocyanates Derived from Fatty Acids by the Trimethylsilyl Azide Modification of the Curtius Rearrangement," <i>Journal of the American Oil Chemists' Society</i> , American Oil Chemists' Society, Champaign, U.S., vol. 49, 1972, pp. 694-695, XP008039249.		
	*	YAMAMOTO et al., "The Survival of Rat Cerebral Cortical Neurons in the Presence of Trophic APP Peptides" <i>J. Neurobiol.</i> 25, 585-594 (1994).		
	*	YOKOKAWA, et al., "The Synthesis of Rat Cerebral Cortical Neurons in the Presence of EF - Hand Type Calcium-Binding Peptides" <i>Chem. Lett.</i> 1627-1630 (1989).		
	*	YOKOYAMA, K., et al., "Development of a corticosteroid incorporated in lipid microspheres (liposteroid)," <i>Drugs Exptl. Clin. Res.</i> XI(9) (1985), pp. 611-620.		
	*	YOSHIDA, et al., "N ⁴ -Behenoyl-1-β-D-Arabinofuranosylcytosine(BH-AC) Pharmacokinetics" <i>Cancer and Chemical Treatment (Cancer and Chemotherapy)</i> 14(6) (1987), Part I pp. 1820-1824 – Japanese Language		
	*	YOSHIDA, et al., "Pharmacokinetics of High Dose Treatments of N ⁴ -Behenoyl-1-β-D-Arabinofuranosylcytosine (BH-AC)" <i>Cancer and Chemical Treatment (Cancer and Chemotherapy)</i> 14(6) (1987), Part I pp. 1820-1824 – English Translation		
	*	YOSHIDA, et al., <i>Cancer and Chemotherapy</i> 14(6) (1987), Part I pp. 1820-1824 – English Abstract		

EXAMINER:	DATE CONSIDERED:
-----------	------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/107,537, filed March 25, 2002, and/or Serial No. 10/108255, filed March 25, 2002, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]